ONT

Oxford Nanopore Technologies PLC

Health Care First-pass screen £1.1bn

460/1000 Overall fit

AI beneficiary 35% 30

Operating leverage 25% 72

Valuation 25% 30

Downside protection 15% 70

First-pass take

Genomics sequencing platform with strong 24% revenue growth and demonstrated operating leverage (EBITDA loss improved £31m despite 22% revenue growth). Well-capitalized with £303m net cash, path to breakeven FY27, but currently loss-making. Zero AI revenue exposure or explicit AI strategy—growth driven by clinical/biopharma adoption, not enterprise AI. No valuation multiples disclosed.

Flags

no-valuation-dataloss-makingcash-burnno-ai-positioningnih-headwindsexecution-risk